Novartis' Cosentyx receives European approval to treat ankylosing spondylitis: 5 notes

Spine

The European Commission granted Novartis International approval for Cosentyx, which treats people with ankylosing spondylitis and psoriatic arthritis, according to MarketWatch

Here are five notes:

 

1. Cosentyx is the first in the interleukin-17A inhibitors class of medicine in Europe.

 

2. The medicine demonstrates sustained clinical benefits in ankylosing spondylitis and psoriatic arthritis. It doesn't exhibit spinal damage in the majority of patients.

 

3. This medicine is the first development in 16 years for the treatment of ankylosing spondylitis.

 

4. About 9,600 patients have taken Cosentyx in clinical trials.

 

5. The medicine is licensed to treat ankylosing spondylitis in adults who saw no improvement with conventional therapy.

 

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Webinars

Featured Podcast

Featured Whitepapers